Table 1.
Additional malignancy recommendations by the National Comprehensive Cancer Network (NCNN)
| Drugs | FDA cancer approval | NCCN cancer recommendation |
|---|---|---|
| Palbociclib | Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer | Soft tissue sarcoma |
| Ceritinib | Anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) | Soft tissue sarcoma |
| Trametinib | Melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test | NSCLC |
| Dabrafenib | Metastatic melanoma with BRAF V600E or V600K mutation | NSCLC |
| Radium-223 | Castration resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease | Osteosarcoma |
| Pomalidomide | Multiple myeloma | Systemic light chain amyloidosis |
| Cabozantinib | Progressive, metastatic medullary thyroid cancer | Kidney cancer; NSCLC |
| Carfilzomib | Relapsed or refractory multiple myeloma | Waldenstroms macroglobulinemia/lymphoplasmacytic lymphoma |
| Crizotinib | Locally advanced or metastatic NSCLC that is anaplastic lymphoma kinase (ALK) positive; metastatic NSCLC with tumors that are ROS1 positive | Soft tissue sarcoma |
| Brentuximab vedotin | Hodgkin lymphoma; anaplastic large cell lymphoma; classic Hodgkin lymphoma | Mycosis fungoides/Sezary syndrome |
| Vemurafenib | Unresectable or metastatic melanoma with BRAFV600E mutation | Hairy cell leukemia; NSCLC |
| Vandetanib | Symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease | Papillary or Hurthle cell thyroid cancer (non-medullary) |